AI Consensus Investment Thesis
GH: Guardant Health Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Guardant Health: 1-Year and 5-Year Forecast Outlook and Rating
Guardant Health (GH) has an immediate Strong Sell consensus AI recommendation, based on 14 AI analysts.
The 1-year target is $148 for , with -4.38% expected return (-4.38% including net dividends) and a SELL ALL rating.
The 5-year target is $164 for , with +5.96% expected return (+5.96% including net dividends) and a PARTIAL SELL rating.
Latest available market price: USD 155, as of 11 Nov 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-11-11.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Guardant Health Flagship Insight
Diagnostic Volume Compounding Collides With High Multiple Valuation Compression
High consensus confirms rapid screening and oncology volume compounding alongside laboratory automation gains. Sharp divergence centers on whether persistent commercial customer acquisition costs and multiple compression under restrictive monetary conditions will severely erode common equity returns before cash-flow breakeven arrives.
How were the Investment Thesis and Forecasts created?
14 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Elon Musk (Visionary)
Machiavelli (Insider)
Ray Dalio (Strategist)
Superintelligence (Anthropologist)
J.P. Morgan (Titan)
Universal Investor (Polymath)
Warren Buffett (Value Purist)
Sherlock Holmes (Whistleblower)
Michael Burry (Vulture)
Ran across these frontier AI models
Google Gemini 3.8 Flash
OpenAI GPT-6 Astra
Anthropic Claude Opus 5
Latest published deep-analysis batch. Audit published forecasts in full transparency
Guardant Health: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest $10,000 in Guardant Health at the latest market close (11 Nov 2026): $10,596 by Sept 2031 versus $13,911 for S&P 500 benchmark.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
The base-case economic argument recognizes Guardant as a preeminent clinical engine whose rapid volume adoption in primary-care screening and therapy selection is temporarily decoupled from shareholder value creation. At twenty times sales in a restrictive monetary regime, current equity valuation discounts frictionless commercial execution and immediate operational leverage. In reality, customer acquisition costs across decentralized primary care networks remain elevated, while statutory private-payer median dynamics threaten to dilute blended average selling prices. The strongest counterargument emphasizes that automated sequencing workflows and high-margin recurring therapy selection provide sufficient contribution margin to achieve self-funding status earlier than consensus models anticipate.
Key insights
- Primary care commercialization imposes heavy distribution friction that dilutes gross margins before network density yields genuine operational leverage.
- Blended average selling prices face structural compression as private-payer commercial contracts expand relative to initial Medicare statutory benchmarks.
- In-the-money convertible note structures and historical balance-sheet deficits ensure that operating growth leaks into dilution rather than per-share value.
Continue reading Guardant Health analysis with Base subscription
See Base accessGuardant Health: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of USD 155, as of 11 Nov 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-11-11.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 14 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 18 Sept 2026 at USD 179. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD.
Scroll the table horizontally to read every column.
| Quarter | Consensus target (USD) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (USD) | Optimistic Advisor Base Case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|---|---|---|---|
| $167 | -7.14% | +7.90% | +7.90% | Initial multiple compression dominates as high interest rates penalize unprofitable duration assets, offsetting accelerating commercial screening test volume and healthy therapy selection demand. | $152 | $185 | $750 | |
| $156 | -6.22% | +0.79% | +0.79% | Full-year financial guidance reveals elevated commercial detailing expenditures, prompting institutional investors to moderate near-term cash flow expectations despite strong underlying specimen growth. | $134 | $187 | $736 | |
| $154 | -1.52% | -0.50% | -0.50% | Expanding oncology companion diagnostic indications and rising minimal residual disease testing volume deliver solid gross profit contributions, sparking a tactical operational relief rally. | $137 | $177 | $743 | |
| $148 | -4.04% | -4.38% | -4.38% | Commercial payer policy implementation introduces realized reimbursement dilution, increasing working capital requirements and keeping forward sales multiples under steady pressure. | $124 | $167 | $755 | |
| $142 | -4.09% | -8.26% | -8.26% | Focus turns toward debt maturity management and corporate cash burn, driving moderate multiple de-rating as markets digest screening salesforce investment requirements into year-end. | $114 | $175 | $776 | |
| $137 | -3.28% | -11.49% | -11.49% | Automated laboratory sequencing workflows begin lowering unit processing costs, mitigating margin drag and reassuring investors of progressing operational leverage across centralized facilities. | $103 | $165 | $787 | |
| $135 | -1.29% | -12.78% | -12.78% | Primary care physician adoption expands, but distribution competition and physician detailing expenses temper net margin progression, keeping equity valuation in a consolidation phase. | $94.6 | $175 | $803 | |
| $137 | +1.34% | -11.49% | -11.49% | Recurring longitudinal monitoring for cancer survivors accelerates, generating predictable high-margin diagnostic streams that stabilize enterprise valuation amid ongoing screening buildouts. | $93.6 | $182 | $812 | |
| $138 | +0.49% | -10.84% | -10.84% | Improving unit economics and decelerating cash burn offset macro discount rate headwinds, allowing shares to find a firm fundamental floor grounded in diagnostic throughput. | $91.5 | $187 | $839 | |
| $141 | +2.34% | -8.90% | -8.90% | Fourth-quarter results demonstrate quarterly operating cash burn approaching breakeven, removing solvency overhang and encouraging accumulation by fundamental healthcare growth allocators. | $83.3 | $192 | $851 | |
| $145 | +2.64% | -6.32% | -6.32% | Initial positive operating cash flow emerges as laboratory automation efficiencies materialize, allowing top-line growth to translate cleanly into corporate margin expansion. | $79.1 | $200 | $872 | |
| $145 | +0.11% | -6.32% | -6.32% | Routine commercial payer fee renegotiations slightly temper average selling prices, inducing mild consolidation while underlying clinical testing volume maintains healthy momentum. | $81.5 | $198 | $886 | |
| $148 | +2.43% | -4.38% | -4.38% | Biopharma partnerships and data licensing agreements generate high-margin milestone receipts, diversifying corporate revenue streams and reinforcing enterprise profitability. | $76.6 | $204 | $910 | |
| $150 | +1.47% | -3.09% | -3.09% | Full-year results confirm sustained operational self-sufficiency, enabling institutional investors to value the business on sustainable cash generation rather than speculative top-line multiples. | $72.8 | $214 | $916 | |
| $154 | +2.36% | -0.50% | -0.50% | International commercialization and multi-cancer trial milestones expand pipeline optionality, supporting steady equity compounding across established clinical channels. | $74.2 | $221 | $937 | |
| $154 | +0.08% | -0.50% | -0.50% | Maturing domestic screening growth rates prompt valuation stabilization, as predictable repeat testing cadences replace early launch enthusiasm across primary care networks. | $71.2 | $223 | $947 | |
| $158 | +2.40% | +2.08% | +2.08% | Expanding operating margins approach mature medtech levels, enabling debt de-leveraging and equity accretion that offset historical convertible share dilution. | $72.0 | $232 | $970 | |
| $159 | +0.92% | +2.73% | +2.73% | Convertible debt settlements expand the diluted share count, creating mild per-share earnings friction that temporarily dampens quarterly equity appreciation. | $69.1 | $236 | $980 | |
| $162 | +2.00% | +4.66% | +4.66% | Demonstrated free cash flow generation easily absorbs capital requirements, driving disciplined earnings-driven share appreciation as the core diagnostic moat widens. | $71.1 | $243 | $1,000 | |
| $164 | +1.04% | +5.96% | +5.96% | The enterprise achieves terminal valuation equilibrium as an established, profitable precision oncology diagnostic leader trading on normalized cash-flow multiples. | $69.0 | $248 | $1,012 |
Show remaining 18 quartersShow first 2 quarters only
All 20 quarters are displayed in the table above.
Guardant Health Stock Analysis & Scenarios Deep Dive
Guardant Health: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? Market consensus views Guardant Health as the anointed winner of blood-based cancer screening, expecting commercial coverage wins and FDA approvals to translate effortlessly into frictionless, software-like profit margins. Euphoric commentary anchors on an enormous addressable screening market, assuming twenty-times-sales multiples are justified by volume compounding while dismissing persistent cash burn and high capital costs.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd materially overestimates the speed at which clinical volume converts into net owner earnings, leaving shares overvalued. The analytical edge lies in recognizing that primary-care customer acquisition incurs heavy commercial friction, while blended test reimbursement will naturally decline as commercial insurers enforce contracted fee schedules below initial Medicare rates. Operating expansion is real, but multiple compression and dilution will constrain equity returns.
Repricing Catalyst
What could make the market recognize and close that gap? Upcoming earnings releases through 2027 showing widening commercial marketing expenses alongside sequential declines in realized revenue per screening test will close the gap. When market participants observe that volume growth fails to rapidly narrow quarterly cash burn, sell-side analysts will be forced to compress revenue multiples toward historical medtech diagnostic averages.
Guardant Health: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Greed
- Volatility Regime
- High Erratic
- Convergence Cycle Position
- Overshoot
Reports agree on high near-term volatility and narrative overshoot, but diverge sharply on cycle duration: bears see imminent valuation collapse, while pragmatists project a multi-year digestion of valuation multiples through revenue growth.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic environment of elevated policy rates and high sovereign benchmark yields is a severe headwind. High borrowing costs penalize long-duration, unprofitable growth companies by increasing the discount rate on distant cash flows and raising the expense of refinancing convertible debt obligations.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive disagreement centers on the magnitude and duration of multiple compression versus operational growth. Bullish perspectives argue that accelerating test volumes and automated laboratory efficiencies will rapidly offset multiple contraction, enabling equity appreciation as free cash flow inflects. Bearish perspectives assert that paying twenty times sales for a business with negative equity and persistent cash burn guarantees severe equity destruction once statutory reimbursement resets take effect. This debate will be resolved by observing whether realized commercial selling prices remain resilient as test volumes scale through 2027.
Guardant Health: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Screening commercial reimbursement cascade | Competitive Positioning | +38% | +55% | FDA approval and commercial coverage inclusion across major benefit managers establish an accessible pathway for colorectal screening. Converting unscreened cohorts drives volume expansion, spreading fixed laboratory overhead across expanding sample counts and lifting recurring revenue. |
| Therapy selection companion diagnostic dominance | Innovation And Product | +26% | +35% | FDA companion diagnostic approvals and minimal residual disease surveillance embed comprehensive genomic profiling directly into standard oncology regimens. Recurring multi-draw testing cadences build high-margin diagnostic revenue streams, insulating baseline cash generation from point-in-time screening cyclicality. |
| Sequencing workflow and assay automation | Operational Efficiency | +20% | +35% | Transitioning high-throughput screening assays to automated sequencing architectures drives down unit processing and reagent costs per sample. This efficiency dividend expands corporate gross margins toward seventy percent, turning fixed laboratory overhead into operational leverage. |
| Biopharma data and translational partnerships | Sector And Industry | +15% | +25% | Pharmaceutical sponsors increasingly integrate liquid biopsy platforms into oncology clinical trials for patient stratification. Companion diagnostic co-development milestones and biomarker data monetization generate high-margin cash inflows, partially diversifying revenues away from commercial reimbursement disputes. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Multiple compression under monetary tightening | Macroeconomic And Macrofinancial | -38% | -8.0% | Trading at an elevated price-to-sales multiple while generating operating losses leaves equity valuation vulnerable to higher discount rates. Sustained restrictive interest rate policy enforces multiple compression toward mature diagnostic peer averages, placing a mechanical ceiling on share appreciation. |
| Commercial payer reimbursement dilution | Regulatory | -24% | -30% | Transitioning from statutory initial Medicare payment rates to negotiated commercial private-payer medians mechanically dilutes blended average selling prices. As commercial contract volume expands, lower realized revenue per test compresses operating gross profits relative to optimistic expectations. |
| High primary care commercial detailing burn | Operational Efficiency | -22% | -30% | Detailing decentralized primary care clinics and direct-to-consumer outreach requires continuous marketing and sales expenditures. These distribution costs absorb laboratory gross profits, keeping operating cash flows negative and deferring corporate self-funding status. |
| Convertible debt dilution and capital deficits | Capital Allocation | -18% | -18% | Carrying over one billion dollars in convertible notes alongside accumulated stockholders' equity deficits creates balance sheet vulnerability. Noteholder conversions expand the common share float, diluting future per-share earnings accretion as the core business approaches operational profitability. |
Guardant Health: What Could Break or Accelerate the Thesis
Event Risk Score: Very High 91/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Private payer median statutory price collapse | 32% | -45% | A sharp reduction in Medicare reimbursement driven by aggressive commercial private-payer discounting could cut unit revenues by over thirty percent. This statutory tariff reset would erase projected screening profit margins, expanding annual cash burn and forcing emergency dilutive equity financing. |
| Precancerous adenoma competitor leapfrogging | 28% | -45% | A competing diagnostic platform demonstrating materially superior advanced adenoma sensitivity alongside high cancer specificity could capture primary care guidelines. Clinicians would relegate blood tests lacking precancer detection to secondary refusal status, severely impairing long-term volume adoption and stranding commercial infrastructure. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| USPSTF Category A guideline parity | 30% | +55% | The Preventive Services Task Force could unexpectedly grant blood screening Category A or B status during upcoming guideline updates, legally mandating commercial coverage without cost-sharing. Eliminating patient copay barriers would instantly accelerate primary care prescription volumes, pulling forward cash-flow breakeven by multiple years. |
| Pan-cancer screening clinical validation breakthrough | 22% | +65% | Pivotal prospective trial data validating multi-cancer early detection panels could trigger expedited regulatory clearance across solid tumors. Expanding addressable screening markets beyond colorectal cancer would position the company as a multi-cancer utility, attracting premium biopharma partnerships and expanding institutional valuation multiples. |
Company Financial AnalysisGuardant Health: Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included. View latest Guardant Health financials here.
Earnings and financials
Top-line revenue demonstrates explosive momentum, driven by rapid adoption of Shield colorectal screening and double-digit volume expansion in therapy selection testing. Recent quarters show revenue growing over forty percent year-over-year, confirming robust physician demand for non-invasive liquid biopsy options. However, this revenue expansion conceals persistent operational unprofitability. Heavy selling, general, and administrative expenditures required to detail decentralized primary care physicians continue to devour gross profits. With annual net losses exceeding four hundred million dollars and negative free cash flow, top-line growth remains subsidized by balance sheet liquidity rather than self-funding operations.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 982M | USD -416.3M | USD -233.1M |
| 2024 | USD 739M | USD -436.4M | USD -274.9M |
| 2023 | USD 563.9M | USD -479.4M | USD -345.5M |
| 2022 | USD 449.5M | USD -654.6M | USD -386.9M |
| 2021 | USD 373.7M | USD -405.7M | USD -284.1M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | USD / USD |
| 2024 | -- | TTM | Loss-making | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Gross profit margins have expanded toward sixty-seven percent, demonstrating authentic manufacturing efficiency as automated sequencing platforms and chemistry optimizations reduce unit processing costs per sample. The core laboratory engine exhibits favorable contribution economics on each test processed. Conversely, operating margins remain deeply submerged in negative territory due to massive commercialization overhead. Selling blood-based screening tests across tens of thousands of family doctors requires an extensive commercial salesforce and marketing expenditure. Sustainable operating profitability depends on physician ordering habits becoming self-sustaining without requiring proportional increases in commercial spending.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD -437.2M | -44.5% | -42.4% |
| 2024 | USD -443.6M | -60.0% | -59.0% |
| 2023 | USD -564.7M | -100.1% | -85.0% |
| 2022 | USD -544.4M | -121.1% | -145.6% |
| 2021 | USD -411M | -110.0% | -108.6% |
Balance sheet and leverage
The balance sheet displays an acute contrast between substantial short-term liquidity and long-term structural leverage. Over one billion dollars in cash and marketable securities provides adequate operational runway for the immediate future, buffering ongoing commercial investments. However, cumulative historical losses have produced a deficit in stockholders' equity, leaving the enterprise with negative book value. Furthermore, gross liabilities include over one billion dollars in convertible notes maturing between 2027 and 2033. Because the stock trades above key conversion strikes, noteholders will likely convert into common shares, eliminating default risk but imposing notable equity dilution.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2025 | USD 1.7B | USD 1.2B | USD 1.3B net debt | USD 508.5M | 4.84x |
| 2024 | USD 1.3B | USD 840M | USD 810.5M net debt | USD 496.1M | 4.68x |
| 2023 | USD 1.4B | USD 1.2B | USD 220.2M net debt | USD 185.1M | 6.54x |
| 2022 | USD 1.4B | USD 1B | USD 1.2B net debt | USD 358.1M | 6.17x |
| 2021 | USD 1.4B | USD 932.7M | USD 881.5M net debt | USD 441M | 5.72x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
Guardant operates an asset-light physical model, keeping direct property and equipment expenditures modest at roughly five percent of revenue. Laboratory facility expansions in recent years provide sufficient physical footprint to process rising specimen throughput without requiring massive industrial machinery buildouts. Instead, capital allocation is concentrated in operational research and development and clinical trial execution. Management commits hundreds of millions annually to optimize sequencing chemistry, automate assay workflows, and validate multi-cancer detection pipelines. This intangible investment preserves technological leadership but defers distributable cash generation into future years.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 48.3M | USD 364.2M |
| 2024 | USD 35.1M | USD 347.8M |
| 2023 | USD 20.5M | USD 367.2M |
| 2022 | USD 77.5M | USD 373.8M |
| 2021 | USD 75M | USD 263.2M |
Behind the synthesisGuardant Health: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 14 advisor opinions. The weights and rationales below are retained from that synthesis.
The consensus centers on an undeniable divergence between clinical volume adoption and shareholder economics. A common pattern across all fourteen analyses is the explosive adoption of blood screening and therapy selection, offset by high commercialization overhead and multiple compression in a tight monetary regime. However, significant correlated assumptions exist regarding the timing of cash-flow breakeven and the severity of terminal multiple contraction. Downweighted opinions assume catastrophic liquidation or extreme multiple collapse below four times sales, which fails to account for verified commercial payer coverage wins and companion diagnostic pricing power. Conversely, top weights are assigned to Polymath models that incorporate forensic balance sheet analysis, verifiable convertible debt dilution mechanics, and realistic average selling price adjustments without succumbing to one-sided extremes.
Individual targets retain their original dates. Returns and ratings use the same latest available market close and dividend assumptions as the Consensus.
All 14 opinions
Consensus weight Allocation: 13.1/100. Weight Allocation Rationale: Outstanding factual verification of Q2 2026 results, detailed convertible debt strike structures, and commercial ASP dilution mechanics. Balances explosive screening volume growth against near-term cash burn realities.
The 1-year target is $167 for , with +7.82% expected return and a BUY rating. The 5-year target is $248 for , with +60.36% expected return and a BUY rating.
Consensus weight Allocation: 11.2/100. Weight Allocation Rationale: Demonstrates rigorous balance sheet cross-checks including the convertible debt maturity profile and realistic dilution mechanics. Grounded heavily in verified SEC filings and FDA companion approvals, presenting a measured multiple compression path.
The 1-year target is $124 for , with -19.64% expected return and a SELL ALL rating. The 5-year target is $142 for , with -7.98% expected return and a PARTIAL SELL rating.
Consensus weight Allocation: 9.3/100. Weight Allocation Rationale: Detailed synthesis of commercial payer cascade dynamics and NovaSeq automation economies. Effectively balances initial reimbursement dilution against compounding primary care test adoption.
The 1-year target is $167 for , with +7.66% expected return and a BUY rating. The 5-year target is $184 for , with +19.07% expected return and a NEUTRAL rating.
Superintelligence AI
- Framework:
- The Anthropologist
- Mode:
- AI RESEARCHER
- AI model:
Google Gemini 3.8 Flash
Consensus weight Allocation: 7.5/100. Weight Allocation Rationale: Captures customer acquisition frictions across decentralized primary care networks and macroeconomic discount rate pressures. However, assumes severe multiple contraction despite strong commercial volume uptake across major payer networks.
The 1-year target is $140 for , with -9.55% expected return and a SELL ALL rating. The 5-year target is $123 for , with -20.38% expected return and a SELL ALL rating.
Consensus weight Allocation: 7.5/100. Weight Allocation Rationale: Accurately highlights the macroeconomic friction of sustained interest rates and duration repricing, but overstates terminal multi-year revenue multiple collapse relative to expanding liquid biopsy operating leverage.
The 1-year target is $162 for , with +4.47% expected return and a NEUTRAL rating. The 5-year target is $248 for , with +60.35% expected return and a BUY rating.
Consensus weight Allocation: 7.5/100. Weight Allocation Rationale: Presents strong insight into statutory reimbursement dynamics and companion diagnostic moats, but incorporates overly aggressive multiple compression assumptions given durable therapy selection testing volume growth.
The 1-year target is $162 for , with +4.40% expected return and a NEUTRAL rating. The 5-year target is $236 for , with +52.23% expected return and a BUY rating.
Superintelligence AI
- Framework:
- The Anthropologist
- Mode:
- AI THINKER
- AI model:
- Google Gemini 3.8 Flash
Consensus weight Allocation: 6.5/100. Weight Allocation Rationale: Provides valid analysis of primary care commercial detailing overhead and negative book equity, but downweights laboratory automation efficiencies and prospective biopharma data monetization opportunities.
The 1-year target is $140 for , with -9.57% expected return and a SELL ALL rating. The 5-year target is $168 for , with +8.51% expected return and a PARTIAL SELL rating.
Consensus weight Allocation: 6.5/100. Weight Allocation Rationale: Sound breakdown of assay automation and companion diagnostic pipelines, though overemphasizes multiple contraction relative to top-line volume elasticity across commercial screening cohorts.
The 1-year target is $157 for , with +1.34% expected return and a PARTIAL SELL rating. The 5-year target is $138 for , with -10.70% expected return and a PARTIAL SELL rating.
Sherlock Holmes AI
- Framework:
- The Whistleblower
- Mode:
- AI RESEARCHER
- AI model:
- Google Gemini 3.8 Flash
Consensus weight Allocation: 6.5/100. Weight Allocation Rationale: Strong forensic accounting focus on cash burn and working capital requirements, though terminal multiples appear overly compressed given the potential for operating leverage post-2028.
The 1-year target is $153 for , with -0.98% expected return and a PARTIAL SELL rating. The 5-year target is $226 for , with +46.10% expected return and a BUY rating.
Consensus weight Allocation: 6.5/100. Weight Allocation Rationale: Insightful political and regulatory analysis surrounding statutory PAMA reimbursement timelines, balanced against realistic commercial friction in decentralized primary care physician detailing.
The 1-year target is $144 for , with -6.67% expected return and a SELL ALL rating. The 5-year target is $156 for , with +0.66% expected return and a PARTIAL SELL rating.
Consensus weight Allocation: 5.6/100. Weight Allocation Rationale: Correctly pinpoints biological limitations regarding precancerous adenoma sensitivity, but projects excessive operational deterioration that understates clinical switching barriers in advanced oncology.
The 1-year target is $130 for , with -16.09% expected return and a SELL ALL rating. The 5-year target is $104 for , with -32.62% expected return and a SELL ALL rating.
Consensus weight Allocation: 4.7/100. Weight Allocation Rationale: Accurately details convertible bond dilution mechanics, yet discounts ongoing laboratory cost-per-test deflation and the durability of recurring therapy selection testing volumes.
The 1-year target is $131 for , with -15.22% expected return and a SELL ALL rating. The 5-year target is $98.8 for , with -36.19% expected return and a SELL ALL rating.
Consensus weight Allocation: 3.7/100. Weight Allocation Rationale: Underweights structural clinical moats in therapy selection and recurring minimal residual disease monitoring, resulting in an excessively punitive downside projection that neglects operational scale efficiencies.
The 1-year target is $130 for , with -16.11% expected return and a SELL ALL rating. The 5-year target is $80.9 for , with -47.70% expected return and a SELL ALL rating.
Consensus weight Allocation: 3.7/100. Weight Allocation Rationale: Highlights real insider selling and potential PAMA statutory reset risks, but adopts an overly extreme liquidation scenario that discounts verified commercial payer coverage expansion.
The 1-year target is $124 for , with -19.69% expected return and a SELL ALL rating. The 5-year target is $69.0 for , with -55.41% expected return and a SELL ALL rating.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v7 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Guardant Health forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher web40 available sources from this batch (85 recorded). The first 15 are shown below; expand to read the rest.
- Premarket Approval (PMA) accessdata.fda.gov
- Premarket Approval (PMA) accessdata.fda.gov
- FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer | FDA fda.gov
- MCGP May 23, 2024 FDA Executive Summary fda.gov
- Federal Reserve Board - Federal Reserve issues FOMC statement federalreserve.gov
- gh-20251231 sec.gov
- gh-20260630 sec.gov
- Guardant Health, Inc. - Form 8-K - FY2026 sec.gov
- Guardant Health, Inc. - Form 8-K - FY2026 sec.gov
- www.businesswire.com businesswire.com
- Guardant Health at Morgan Stanley conference: shield scales, cdx gains By Investing.com ca.investing.com
- Colorectal Cancer | American Cancer Society cancer.org
- Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway exactsciences.com
- Guardant Health (GH) Just Gave Investors Something To Think About finance.yahoo.com
- Guardant Health Inc (GH) (Q2 2026) Earnings Call Highlights: Revenue Surges 44% on FDA Approval ... finance.yahoo.com
Show 25 more sources
- Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering finance.yahoo.com
- Guardant Health’s Big Run Rides On Shield And Lower Test Costs - Finimize finimize.com
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S. - Freenome freenome.com
- Freenome Announces Exclusive License Agreement with Exact Sciences to Commercialize Freenome’s Blood-Based Screening Test for Colorectal Cancer - Freenome freenome.com
- Guardant Health’s Shield Colorectal Cancer Blood Test Garners CMS Advanced Diagnostic Status globalbioclinical.com
- Earnings call transcript: Guardant Health tops Q2 2026 estimates as shares jump By Investing.com investing.com
- Guardant Health prices upsized $350 million convertible notes offering By Investing.com investing.com
- Guggenheim raises Guardant Health stock price target on Shield data By Investing.com investing.com
- Guardant Health Receives ADLT Status From CMS for Shield Blood Test | Guardant Health Investor Relations investors.guardanthealth.com
- Guardant Health Receives ADLT Status From CMS for Shield Blood Test | Guardant Health Investor Relations investors.guardanthealth.com
- Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook | Guardant Health Investor Relations investors.guardanthealth.com
- Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance | Guardant Health Investor Relations investors.guardanthealth.com
- Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance | Guardant Health Investor Relations investors.guardanthealth.com
- Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening | Guardant Health Investor Relations investors.guardanthealth.com
- Shield Blood Test Yields High Sensitivity, Specificity for CRC Screening in Expansion Cohort of Average-Risk Adults | OncLive onclive.com
- Press Releases pressroom.cancer.org
- 2025 10-K-2026-02-26-15-35 s206.q4cdn.com
- Shield™ for HCPs | Shield™ by Guardant Health shieldcancerscreen.com
- rohk5k51 humana centene and medicare coverage will increase screening access jv3q simplywall.st
- Guardant Health Stock Rises As FDA And Wall Street Back Growth Story - StocksToTrade stockstotrade.com
- Guardant Health posts $334,978K Q2 revenue, loss | GH Quarterly Report (10-Q) stocktitan.net
- Guardant Health revenue rises but losses persist | GH Quarterly Report (10-Q) stocktitan.net
- Guardant Health prices $350 million convertible notes offering streetinsider.com
- guardant health co ceo makes a multi million dollar stock sale insider trading tipranks.com
- Guardant Health reports Q2 2026 revenue $335.0M, raises 2026 revenue guidance to $1.34–1.36B tradingview.com
45 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
Archived context covering 2025-01-01 to 2025-12-31. Its recorded scope includes technology and capital cycle; trade and industrial policy; monetary policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 90.8K bytes
- Words
- 13.3K words
- Characters
- 90.8K characters
- Est. tokens (characters ÷ 4)
- 22.7K tokens
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Archived context covering 2026-01-01 to 2026-09-20. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 84.8K bytes
- Words
- 12.4K words
- Characters
- 84.8K characters
- Est. tokens (characters ÷ 4)
- 21.2K tokens
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2016-12-31–2025-12-31, 10 periods; Quarterly fiscal periods: 2023-09-30–2026-06-30, 12 periods.
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.
Guardant Health: forecast questions
What is Guardant Health (GH)'s 1-year price forecast?
Guardant Health's 1-year target is $148 for Sept 2027. The current AI rating is SELL ALL. The expected return from the recorded close is -4.38%, or -4.38% modeled return including net dividends. Latest available market price: USD 155, as of 11 Nov 2026. The target date is fixed; this is not a new rolling forecast.
What is Guardant Health (GH)'s 5-year price forecast?
Guardant Health's 5-year target is $164 for Sept 2031. The current AI rating is PARTIAL SELL. The expected return from the recorded close is +5.96%, or +5.96% modeled return including net dividends. Latest available market price: USD 155, as of 11 Nov 2026. The target date is fixed; this is not a new rolling forecast.
How can I compare the AI opinions and audit past Guardant Health forecasts?
14 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History preserves earlier published batches; their figures describe their original publication, not today's outlook.
How does an AI-generated forecast for Guardant Health differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Guardant Health is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
If iPulse AI produces thousands of investment reports - work estimated to require over 100,000 traditional analyst hours - isn't that just "AI slop" at scale?
No. iPulse AI produces AI-generated research at scale, but the purpose is depth of analysis, comparison, and accountability. The number of reports is a consequence of the research process; it is not the goal.
iPulse AI does not produce thin copies of existing websites, articles, or investment reports. We use frontier models as an Analytical Intelligence layer. Our Financial Experts select, validate, curate, and supply the input data, including proprietary inputs, so the models work from a prepared evidence base.
In Researcher mode, models can also search the web to check current information, test assumptions, and investigate evidence that may be missing from the supplied data. This can include lobbying expenditure, management developments, regulatory decisions, or other facts relevant to a particular investment thesis. Thinker mode focuses on deep reasoning over the supplied data and context.
Our process goes much further than asking ChatGPT to evaluate a stock. Our team designs structured investment frameworks inspired by the approaches of influential investors, economists, political thinkers, and technological visionaries. These are AI analytical frameworks, not reports written or endorsed by the people who inspired them.
Each asset is analyzed separately through multiple frameworks and configurations, using specialized inputs and task instructions. Different perspectives examine different questions: valuation, business quality, technological disruption, macroeconomic conditions, political influence, financial risks, and more.
Cloud infrastructure allows these workflows to run at scale. That scale also comes with quality assurance at scale: up to 30% of report-generation attempts fail our QA checks. We rerun failed attempts until a clean report passes those checks. Users are presented only with reports that have passed QA.
This explains the volume. The value comes from what we do with the analysis.
A second layer synthesizes the individual reports into an asset-level consensus. This is where we recommend starting when researching a particular asset: it brings together the central thesis, supporting evidence, risks, and disagreements while preserving access to the underlying opinions.
We then compare assets through our proprietary iPulse AI Consensus Score, whose methodology is publicly explained. This helps users move from understanding one asset to comparing opportunities across the analyzed universe.
A further research and editorial layer examines leading candidates, checks current evidence, and develops focused Editorial Top Picks across broad-market and dedicated asset categories. Human editors review the evidence and approve each published edition. For example, explore our Best Long-Term Investments.
But the process does not end when a report is published. We preserve past forecasts so users with the relevant subscription can inspect what the system actually said and compare it with subsequent market outcomes. As more forecasts reach their target dates, the historical record becomes more useful for evaluating which approaches worked, which failed, and under what conditions.
We publish research on our website, arXiv, and Zenodo, alongside explanatory writing on Medium. We use the evidence to refine our data, frameworks, validation, and workflows, and document important findings in Lessons Learned.
The standard we ask users to judge us by is the reasoning, evidence, and historical record behind the research.
How does the iPulse AI Engine work?
The engine runs AI advisor configurations against a shared set of research inputs. The engine history explains the research workflow and what changed between versions.